Member Info for dickie3times

You can't tell profit takers not to derisk...it hsppens on all stocks. Steady as she goes. Gls

....little here, little there !

Who Dares....

?

Sp trying to breakout above p.0012p...when it does then a new low of 0.0015p possible. Depends on WHO DARES to HOLD

Steve HE1 is on my short list but i missed the lows...GL

Steve..i did look into HE1 but missed thr lows in rarly March....still looking and waiting for an entry but ny the chart it looks like a constant rise up...gla

BE BOLD....
..........HOLD

GLA

Long term holder....rarely post but my faith in MKA has been continually being boosted....

https://www.investegate.co.uk/mkango-resources-ltd--mka-/rns/mkango-announces-results-of-flotation-piloting/202105040700103027X/

GLA

let's hope they get taken to court and get there just desert'
THEIR just DESSERTS

LOL

https://total-market-solutions.com/?s=Hemo

My luck must be in...topped up this morning!

Dr Vladislav Sandler, CEO of Hemogenyx, said: "2020 was an exceptionally productive year for Hemogenyx Pharmaceuticals, both scientifically and commercially. Not only did we achieve significant progress with our existing product candidates, we were also able to leverage our proprietary technologies and expertise to further broaden and diversify our product pipeline. We entered into a collaboration with the University of Pennsylvania, thereby advancing HEMO-CAR-T toward clinical trials, completed the developmental stage of our collaboration with GlobalCo by choosing a CDX antibody to be developed into clinical trials, and established a novel platform technology, CBR, for the treatment of a range of conditions including viral infections, in particular COVID-19, as well as certain types of cancer."

https://www.investegate.co.uk/hemogenyx-pharma-plc--hemo-/rns/final-results/202104301427202811X/

Great RNS....

Dr Vladislav Sandler, CEO of Hemogenyx, said: "2020 was an exceptionally productive year for Hemogenyx Pharmaceuticals, both scientifically and commercially. Not only did we achieve significant progress with our existing product candidates, we were also able to leverage our proprietary technologies and expertise to further broaden and diversify our product pipeline. We entered into a collaboration with the University of Pennsylvania, thereby advancing HEMO-CAR-T toward clinical trials, completed the developmental stage of our collaboration with GlobalCo by choosing a CDX antibody to be developed into clinical trials, and established a novel platform technology, CBR, for the treatment of a range of conditions including viral infections, in particular COVID-19, as well as certain types of cancer."

https://www.investegate.co.uk/hemogenyx-pharma-plc--hemo-/rns/final-results/202104301427202811X/

https://www.fool.co.uk/investing/2021/04/28/5-reasons-im-avoiding-supplyme-syme-shares/

I am 30% down...and gradually losing it.
GLA

Too trie George...he does give me the odd tip. He works for JP Morgan in the Edinburgh branch and when he invests he has to declare his investment to the management ie in case he had inside info...

Sorry i am 60% down. Bought at 4.2p

My son asked me for 3 tips and i suggested ICON at 000.75p......Alien at 0.9p and HEMO at 4.5p. He just texted me to say that he didn't 6put any money into Hemo as he felt that at over 3.5p was too eXpendive......glad he didn't... a big relief for me. Although i an currently 90% down

Trade some and hold some. Great little earner?

1.39p

Happyhaddock....."Clearly UFO has been somewhat undervalued for a while and the move up is good to see, but lets remember price moves are only meaningful when there is material evidence to support and hold them... in that respect nothing has changed"

***Maybe news is inbound....7am me thinks

Hmmmm?

The Company has terminated the Transaction Agreement in accordance with its terms as MMIH has not met its Total Funding Commitment (defined below) under the Transaction Agreement, and is taking steps to recover the shares transferred to MMJV under the Transaction Agreement and is taking advice from Singapore counsel on the appropriate steps forward.

The consideration payable by MMIH under the Transaction Agreement comprised:

i) a funding commitment of up to US$2.25m (approximately £ 1.82m) to be deployed, inter alia, to satisfy the Exploration Period Requirements;

ii) subject to the MPSA being renewed following completion of the Exploration Period Requirements to the satisfaction of the relevant Philippine authorities, a further funding commitment of up to S$5.5m (approximately £ 3.23m) to be applied in undertaking a definitive feasibility study; and

iii) the issue of S$10m (approximately £ 5.87m) of shares in CHX or other listed entity holding MMJV on the Singapore Stock Exchange ("ListCo"), subject to successful completion of the abovementioned RTO Transaction.

The funding commitments in i) and ii) collectively are the "Total Funding Commitment".

Bezant, will explore and pursue options including the possibility of re-positioning the Mankayan project within the Company's portfolio of copper and gold assets. The Company will provide a further update(s) as and when appropriate.

For further information....
Hmmmm?

"Online trading across all sectors is declining as more and more people travel to shops" "Trade picking up everywhere as we gradually come out of lockdown" !